Xeris Biopharma Holdings, Inc.
NASDAQ:XERSBiotechnology
+$0.04 today
- Market cap
- $3.10B
- Beta
- 0.90
- P/E (TTM)
- 98.7
- EPS (TTM)
- $0.07
Volume 2.76M
Average 1.66M
XERS Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Xeris Biopharma Holdings, Inc.NASDAQ: XERS
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 91.2% from a year ago
Cash & equivalents stood at $111.75M at the end of Q1 FY2026, up 91.2% from a year earlier and up 0.6% from the prior quarter. Over 3 fiscal years it compounded at -3.1% a year.
Context
- Cash & equivalents amounted to 28.5% of total assets at the end of Q1 FY2026, up 10.0 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +91.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 111.04M USD
- Year-over-year change
- +55.0%
- 4-year CAGR
- +13.3%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 111.04M | +55.0% |
| FY2024 | 2024-12-31 | 71.62M | +6.2% |
| FY2023 | 2023-12-31 | 67.45M | -44.7% |
| FY2022 | 2022-12-31 | 121.97M | +81.3% |
| FY2021 | 2021-12-31 | 67.27M | — |
Cash & Equivalents vs competitors
How XERS compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +91.2% is the 2nd highest of 9, against a peer median of +9.9%.
- Cash & equivalents amounts to 28.5% of total assets for XERS, versus a peer median of 29.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | €964.36M EUR | +78.9% | +11.5% | 39.7% | |
| Mar 2026 | $242.65M USD | -0.9% | +14.1% | 88.2% | |
SEPNSepterna, Inc. | Sep 2026 | $167.12M USD | -47.8% | +58.0% | 27.0% |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $161.69M USD | -27.5% | +46.0% | 32.3% |
| Mar 2026 | $111.75M USD | +91.2% | -3.1% | 28.5% | |
| Jun 2026 | $111.04M USD | +8.1% | +22.0% | 12.5% | |
| Mar 2026 | $54.08M USD | +111.1% | +25.9% | 96.3% | |
| Mar 2026 | $52.83M USD | +11.7% | +2.4% | 7.1% | |
| Mar 2026 | $19.66M USD | +12.9% | +16.7% | 20.1% | |
| Peer median (excluding XERS) | — | +9.9% | +19.4% | 29.6% | |
Competitors are the stored peer set for XERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 67.27M | 121.97M | 67.45M | 71.62M | 111.04M |
| Short-term Investments | 35.16M | 0 | 5M | 0 | 0 |
| Net Receivables | 17.46M | 30.83M | 39.2M | 40.42M | 51.05M |
| Inventory | 18.12M | 24.74M | 38.84M | 48.18M | 68.67M |
| Other Current Assets | 0 | 9.29M | 5.78M | 7.45M | 9.55M |
| Total Current Assets | 142.6M | 186.82M | 156.26M | 167.66M | 240.31M |
| Property, Plant & Equipment (Net) | 6.63M | 9.51M | 29.18M | 28.21M | 27.06M |
| Goodwill | 22.86M | 22.86M | 22.86M | 22.86M | 22.86M |
| Intangible Assets | 131.45M | 120.61M | 109.76M | 98.92M | 88.08M |
| Long-term Investments | 0 | 0 | 0 | 4.12M | 0 |
| Tax Assets | 0 | 0 | 0 | 6.09M | 0 |
| Other Non-current Assets | 829K | 4.73M | 4.54M | (4.81M) | 5.22M |
| Total Non-current Assets | 161.77M | 157.7M | 166.34M | 155.4M | 143.21M |
| Total Assets | 304.36M | 344.52M | 322.6M | 323.06M | 383.53M |
| Account Payables | 8.92M | 4.61M | 11.57M | 2.29M | 3.08M |
| Short-term Debt | 0 | 0 | 0 | 15.1M | 6.23M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 25.63M | 27.23M | 51.43M | 39.75M | 100.27M |
| Total Current Liabilities | 79.04M | 73.62M | 95.19M | 100.44M | 109.57M |
| Long-term Debt | 88.07M | 187.08M | 190.93M | 217.01M | 31.53M |
| Deferred Tax Liabilities | 4.94M | 3.52M | 2.27M | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 37.08M | 25.72M | 6.23M | 1.97M | 228.73M |
| Total Non-current Liabilities | 130.09M | 225.71M | 234.19M | 252.23M | 260.26M |
| Total Liabilities | 209.13M | 299.34M | 329.38M | 352.68M | 369.84M |
| Common Stock | 13K | 14K | 14K | 15K | 17K |
| Retained Earnings | (460.11M) | (554.77M) | (617.03M) | (671.86M) | (671.31M) |
| Accumulated OCI | (31K) | (23K) | (25K) | (25K) | (25K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 95.23M | 45.19M | (6.78M) | (29.62M) | 13.69M |
| Total Debt | 88.07M | 198.06M | 229.19M | 271.45M | 37.76M |
| Net Debt | 20.8M | 76.09M | 161.74M | 199.83M | (73.28M) |
Xeris Biopharma Holdings, Inc.
NASDAQ:XERS
Intrinsic Alpha fair value
Locked
Current Price
$16.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.